Showing results (21-30 of 41) with videos related to
Sort By:
Pageof 5
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 25, 2021
The influence of brain metastases on the central nervous system effects of methylnaltrexone: a post hoc analysis of 3 randomized, double-blind studiesDarren M Brenner, Neal E Slatkin, Nancy Stambler, et al.Journal of Opioid Management|January 16, 2010
Methylnaltrexone potentiates body weight and fat reduction with leptinChun-Su Yuan, Shi Sun, Anoja Attele, et al.Clinical and Translational Science|June 9, 2022
A randomized, placebo-controlled study to evaluate safety and pharmacokinetics of inhaled ribavirinPeter Couroux, Alexandre Brkovic, Jason L Vittitow, et al.Journal of Palliative Medicine|May 15, 2015
Fixed-Dose Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: Results of a Randomized, Placebo-Controlled Study and Open-Label ExtensionJanet Bull, Charles V Wellman, Robert J Israel, et al.Journal of Pain Research|February 17, 2023
Subcutaneous Methylnaltrexone as Treatment for Opioid-Induced Constipation in Patients with Advanced Cancer and Noncancer Illnesses: A Post Hoc Analysis of Two Clinical TrialsEric D Shah, Bruce H Chamberlain, Michelle Rhiner, et al.Clinical Pharmacology in Drug Development|January 28, 2023
A Randomized, Double-Blind, Parallel Design Thorough QT Study With a Nested Crossover to Compare the Cardiac Safety of Amiselimod With Placebo and Positive Control in Healthy VolunteersJimin Lee, Robert Lester, Terry O'Reilly, et al.AIDS Research and Therapy|August 25, 2009
Protease inhibitor-induced nausea and vomiting is attenuated by a peripherally acting, opioid-receptor antagonist in a rat modelChun-Su Yuan, Chong-Zhi Wang, Sangeeta R Mehendale, et al.Journal of Pain and Symptom Management|August 29, 2009
Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illnessBruce H Chamberlain, Karen Cross, Jaron L Winston, et al.American Journal of Clinical Dermatology|September 8, 2019
Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II StudyMark G Lebwohl, Andrew Blauvelt, Alan Menter, et al.Infectious Diseases and Therapy|July 24, 2021
Ribavirin Aerosol in the Treatment of SARS-CoV-2: A Case SeriesEmanuela Messina, Anna Danise, Giulio Ferrari, et al.Pageof 5